Sign In
Buy BEAM
$29.55
+0.590 (+2.04%)
At Close: Jun 03, 2026
Could a Recent Gene Editing Breakthrough Make This Cathie Wood Stock a Buy?
07:57am, Sunday, 12'th Sep 2021
One biotech could have the inside track to profit from a major achievement in CRISPR gene editing.
Beam Therapeutics to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
06:30am, Wednesday, 08'th Sep 2021
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Jo
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
05:30pm, Friday, 03'rd Sep 2021
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic R
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
07:30am, Friday, 03'rd Sep 2021
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic R
The 3 Best Biotech Stocks to Buy Right Now
06:55am, Friday, 27'th Aug 2021
Let your portfolio reflect your personality.
Beam Therapeutics: If You Buy Into The Technology, Buy Into The Stock
07:01am, Wednesday, 25'th Aug 2021
Beam is pioneering a new approach to gene therapy known as base editing.
3 Stocks to Avoid if Cathie Wood's ARK ETF Falls
07:20am, Saturday, 21'st Aug 2021
They likely to do the worst if Michael Burry is right.
How Are Genomics ETFs Responding to Q2 Earnings?
10:00am, Saturday, 14'th Aug 2021
Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
09:22am, Tuesday, 10'th Aug 2021
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of -63.79% and -99.98%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock
Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results
06:30am, Tuesday, 10'th Aug 2021
Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021
Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
04:48pm, Wednesday, 04'th Aug 2021
Beam Therapeutics Inc. (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beam Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
06:30am, Tuesday, 03'rd Aug 2021
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giu
3 Healthcare Stocks That Could Make You Rich
05:55am, Wednesday, 21'st Jul 2021
They're disruptors that could change healthcare.
Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week
11:02am, Friday, 16'th Jul 2021
After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.
A Comprehensive Guide to Genomic ETFs
05:17pm, Friday, 09'th Jul 2021
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
